<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820311</url>
  </required_header>
  <id_info>
    <org_study_id>0136</org_study_id>
    <nct_id>NCT02820311</nct_id>
  </id_info>
  <brief_title>Thorough QT (TQT) Study of TD-4208 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled, 4-Period Crossover Thorough QT Study to Evaluate the Effect of a Single Dose of TD-4208 on Cardiac Repolarization in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mylan Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mylan Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if TD-4208, an investigational drug being developed&#xD;
      to treat people with chronic obstructive pulmonary disease (COPD), has any effect on the&#xD;
      electrical activity of the heart.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change-from-baseline in corrected QT</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration Cmax</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Predose to 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Cardiac Repolarization in Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>TD-4208 175 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-4208 700 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for TD-4208</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open-label</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208 175 mcg</intervention_name>
    <description>via nebulizer</description>
    <arm_group_label>TD-4208 175 mcg</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-4208 700 mcg</intervention_name>
    <description>via nebulizer</description>
    <arm_group_label>TD-4208 700 mcg</arm_group_label>
    <other_name>revefenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for TD-4208</intervention_name>
    <description>via nebulizer</description>
    <arm_group_label>Placebo for TD-4208</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin 400 mg</intervention_name>
    <description>oral</description>
    <arm_group_label>Moxifloxacin 400 mg</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has a body mass index (BMI) of 19 to 32 kg/m2, inclusive, and weight of at&#xD;
             least 55 kg.&#xD;
&#xD;
          -  Subject is able to communicate well with the investigator and to comply with the study&#xD;
             procedures, requirements, and restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a prior history of myocardial infarction, acute coronary syndrome,&#xD;
             cerebrovascular accident, transient ischemic attack, ventricular tachycardia, atrial&#xD;
             fibrillation, personal or known family history of congenital long QT syndrome or known&#xD;
             family history of sudden death with unknown cause, a pacemaker or implantable&#xD;
             cardioverter defibrillator, cardiac or cerebral stent placement or angioplasty, or&#xD;
             clinically significant valvular heart disease.&#xD;
&#xD;
          -  Subject has evidence or history of clinically significant allergic (except for&#xD;
             untreated, asymptomatic, seasonal allergies at time of dosing), hematologic,&#xD;
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or&#xD;
             neurological disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thorough QT (TQT)</keyword>
  <keyword>cardiac safety</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

